Hormone replacement therapy: To use or not to use?

Medical Journal of Australia

Volumn 178, Issue 12, 2003, Pages 630-633

  Baber, Rodney J ^a   O'Hara, Justine L ^a   Boyle, Frances M ^a  

^a University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; GLUCOSE; INSULIN; LIPOPROTEIN; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; STEROID; TIBOLONE;

AGE; BREAST CANCER; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COUNSELING; DEMENTIA; DENTITION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; ESTROGEN THERAPY; FRACTURE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LONG TERM CARE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; META ANALYSIS; OSTEOPOROSIS; PRESCRIPTION; QUALITY OF LIFE; REVIEW; RISK; RISK BENEFIT ANALYSIS; SKELETON; SKIN; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION; UROGENITAL TRACT DISEASE; VEIN THROMBOSIS;

EID: 0037829742     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05389.x     Document Type: Review

References (26)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Writing group for the Women's Health Initiative. JAMA 2002; 288: 321-333.
2. Patel A, Norton R, McMahon S. The HRT furore: Getting the message right. Med J Aust 2002; 177: 345-346.
3. Australian Pharmaceutical Index. Sydney: Intercontinental Medical Statistics (IMS) Health Australia Pty Ltd. 2003.
4. Vickers M, Meade T, Darbyshire J. WISDOM: History and early demise - Was it inevitable? Climacteric 2002; 5: 317-325.
5. MacLennan A, Wilson D, Taylor A. Hormone replacement use over a decade in an Australian population. Climacteric 2002; 5: 21-26.
6. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane review). The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
7. Davis SR. Menopause: New therapies. Med J Aust 2003; 178: 634-637.
8. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
9. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Annu Rev Public Health 1998; 19: 55-72.
10. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941.
11. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.
12. Laine C. Postmenopausal hormone therapy: How could we have been so wrong? Ann Intern Med 2002; 17: 290.
13. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
14. Herrington D, Reboussin D, Brosnihan K, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000; 343: 522-529.
15. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long term effects of hormone replacement therapy. Lancet 2002; 360: 943-944.
16. Mikkola T, Clarkson T. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605-619.
17. Mendelsohn ME, Karas RH. The protective effect of estrogen of the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
18. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 without breast cancer Lancet 1997; 350: 1047-1059.
19. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust 1995; 162: 491-493.
20. Grodstein F, Martinez E , Platz E, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998; 128: 705-712.
21. Liehr JG. Breast carcinogenesis and its prevention by inhibition of estrogen genotoxicity. In: Miller WR, Ingle JN, editors. Endocrine Therapy in Breast Cancer. New York: Marcell Dekker, 2002.
22. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal desity. PEPI Investigators. Ann Intern Med 1999; 130: 262-269.
23. Lacey V, Mink P, Lubin J, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002, 288: 334-343.
24. Viscoli C, Brass L, Kernan W, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-1249.
25. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy for cognitive function in postmenopausal women (Cochrane review). The Cochrane Library, Issue 3, Oxford: Update Software.
26. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 680-690.